TROPION Breast Respond in 1L TNBC

StatusNot Yet Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
There are no real-world data available on the effectiveness and safety of Dato-DXd in adult patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy. This NIS will investigate the effectiveness of Dato-DXd, the demographic and clinical characteristics of the patients, and treatment patterns.
Trial Details
NCT Number NCT07867470
Lead Sponsor Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Conditions
(from sponsor)		 Unresectable Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer
Related terms Triple Negative Breast Neoplasms
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov